Vascular Group

VRG Therapeutics announces validation of its AI-powered drug discovery platform and opens USD 15 million funding round

Press release BUDAPEST, HUNGARY, February 20, 2024/ — VRG Therapeutics(VRG Tx), a biotechnology R&D company focusing on miniprotein pharmaceuticals and cellular & gene therapy (CGT) products has announced the successful experimental verification of its proprietary, artificial intelligence-(AI)-powered drug discovery technology. Using the company’s established, directed evolution based miniprotein platform, VRG Tx has previously demonstrated […]

MBH Bank’s Macronome Macroverse conference

We are proud to share that our Managing Director, Zalán Péterfi has participated at the second roundtable of MBH Bank’s Macronome Macroverse conference, where the results and challenges of the Hungarian innovation ecosystem and Hungary’s position in European terms were discussed. Participants also talked about how to improve Hungary’s innovation and technology situation.

Recognition of our student researcher

We are happy to announce that Ádám Jenőfalvi, a student researcher at VRG Therapeutics won first prize at the student association conference („TDK”) at Budapest University of Technology and Economics in Section Biotechnology, Biochemistry and Food Sciences. His thesis describes the engineering of a recombinant live biotherapeutic product (rLBP) to treat inflammatory bowel diseases. Congratulations […]

Startup Breeding 2023 Milan Awards

We are happy and thrilled to announce that our Kv1.3 pitch was chosen as “Best Innovative Business Proposal” by a board of investors on Startup Breeding, an annual event of Cluster Nazionale Scienze della Vita ALISEI, the Italian National Cluster for Life Sciences. Furthermore, we received the Special Awards of 2i3T – Innovative Companies Incubator […]

Bio Europe 2023 Munich

We are thrilled to announce that VRG Therapeutics has been selected to present in front of top-tier VC investors in the Startup Spotlight competition at Bio Europe 2023, organized with the support of Bayer Co.Lab incubator. We pitch our Kv1.3 asset aiming to cure autoimmune diseases. You’ll have the opportunity to meet with Zalán Péterfi […]